Noema Pharma to attend Swiss Biotech Day and the UBS Biotech Private Company Symposium in September 2021

BASEL, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) — Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces it will attend two upcoming investor events:

  • Swiss Biotech Day, in-person in Basel, September 6, 2021
    Luigi Costa will meet with investors in one-on-one meetings
  • The UBS Biotech Private Company Symposium, virtual, September 22-23, 2021
    Luigi Costa will be presenting and available for Q&A on September 23rd at 16:00 CET

About Noema Pharma
Noema Pharma ( is a Swiss-based company targeting orphan neurological disorders characterized by imbalanced neuronal networks. The company is developing four mid-clinical-stage therapeutic products in-licensed from Roche and with strong safety packages. Lead product NOE-101, an mGluR5 inhibitor, is Phase 2b-ready for two indications: persistent seizures in Tuberous Sclerosis Complex (TSC) and severe pain in Trigeminal Neuralgia (TN). NOE-105, a PDE10A inhibitor, is in preparation for Phase 2b testing to treat Tourette Syndrome. The Company is undertaking validation studies in undisclosed indications for two additional clinical-stage assets, NOE-109, an mGluR2/3 inhibitor, and NOE-115, a triple re-uptake inhibitor. Noema Pharma was founded with the leading venture capital firm Sofinnova Partners. Investors include Polaris Partners, Gilde Healthcare, Invus and Biomed Partners.


Noema Pharma
Luigi Costa
Chief Executive Officer
LifeSci Advisors – Guillaume van Renterghem
+41 (0) 76 735 01 31
LifeSci Advisors – Bernhard Schmid
+41 (0) 44 447 12 21


error: Content is protected !!